Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association

Richard A. Insel, Jessica L. Dunne, Mark A. Atkinson, Jane L. Chiang, Dana Dabelea, Peter A. Gottlieb, Carla J. Greenbaum, Kevan C. Herold, Jeffrey P. Krischer, Ake Lernmark, Robert E. Ratner, Marian J. Rewers, Desmond A. Schatz, Jay S Skyler, Jay M Sosenko, Anette G. Ziegler

Research output: Contribution to journalArticle

204 Citations (Scopus)

Abstract

Insights fromprospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.

Original languageEnglish (US)
Pages (from-to)1964-1974
Number of pages11
JournalDiabetes Care
Volume38
Issue number10
DOIs
StatePublished - Oct 1 2015

Fingerprint

Type 1 Diabetes Mellitus
Autoimmunity
Precision Medicine
Autoantibodies
Longitudinal Studies
Odds Ratio
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., ... Ziegler, A. G. (2015). Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association. Diabetes Care, 38(10), 1964-1974. https://doi.org/10.2337/dc15-1419

Staging presymptomatic type 1 diabetes : A scientific statement of jdrf, the endocrine society, and the American diabetes association. / Insel, Richard A.; Dunne, Jessica L.; Atkinson, Mark A.; Chiang, Jane L.; Dabelea, Dana; Gottlieb, Peter A.; Greenbaum, Carla J.; Herold, Kevan C.; Krischer, Jeffrey P.; Lernmark, Ake; Ratner, Robert E.; Rewers, Marian J.; Schatz, Desmond A.; Skyler, Jay S; Sosenko, Jay M; Ziegler, Anette G.

In: Diabetes Care, Vol. 38, No. 10, 01.10.2015, p. 1964-1974.

Research output: Contribution to journalArticle

Insel, RA, Dunne, JL, Atkinson, MA, Chiang, JL, Dabelea, D, Gottlieb, PA, Greenbaum, CJ, Herold, KC, Krischer, JP, Lernmark, A, Ratner, RE, Rewers, MJ, Schatz, DA, Skyler, JS, Sosenko, JM & Ziegler, AG 2015, 'Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association', Diabetes Care, vol. 38, no. 10, pp. 1964-1974. https://doi.org/10.2337/dc15-1419
Insel, Richard A. ; Dunne, Jessica L. ; Atkinson, Mark A. ; Chiang, Jane L. ; Dabelea, Dana ; Gottlieb, Peter A. ; Greenbaum, Carla J. ; Herold, Kevan C. ; Krischer, Jeffrey P. ; Lernmark, Ake ; Ratner, Robert E. ; Rewers, Marian J. ; Schatz, Desmond A. ; Skyler, Jay S ; Sosenko, Jay M ; Ziegler, Anette G. / Staging presymptomatic type 1 diabetes : A scientific statement of jdrf, the endocrine society, and the American diabetes association. In: Diabetes Care. 2015 ; Vol. 38, No. 10. pp. 1964-1974.
@article{b11af9c1ab534b11a8d7bdec2840e749,
title = "Staging presymptomatic type 1 diabetes: A scientific statement of jdrf, the endocrine society, and the American diabetes association",
abstract = "Insights fromprospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.",
author = "Insel, {Richard A.} and Dunne, {Jessica L.} and Atkinson, {Mark A.} and Chiang, {Jane L.} and Dana Dabelea and Gottlieb, {Peter A.} and Greenbaum, {Carla J.} and Herold, {Kevan C.} and Krischer, {Jeffrey P.} and Ake Lernmark and Ratner, {Robert E.} and Rewers, {Marian J.} and Schatz, {Desmond A.} and Skyler, {Jay S} and Sosenko, {Jay M} and Ziegler, {Anette G.}",
year = "2015",
month = "10",
day = "1",
doi = "10.2337/dc15-1419",
language = "English (US)",
volume = "38",
pages = "1964--1974",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "10",

}

TY - JOUR

T1 - Staging presymptomatic type 1 diabetes

T2 - A scientific statement of jdrf, the endocrine society, and the American diabetes association

AU - Insel, Richard A.

AU - Dunne, Jessica L.

AU - Atkinson, Mark A.

AU - Chiang, Jane L.

AU - Dabelea, Dana

AU - Gottlieb, Peter A.

AU - Greenbaum, Carla J.

AU - Herold, Kevan C.

AU - Krischer, Jeffrey P.

AU - Lernmark, Ake

AU - Ratner, Robert E.

AU - Rewers, Marian J.

AU - Schatz, Desmond A.

AU - Skyler, Jay S

AU - Sosenko, Jay M

AU - Ziegler, Anette G.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Insights fromprospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.

AB - Insights fromprospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum that progresses sequentially at variable but predictable rates through distinct identifiable stages prior to the onset of symptoms. Stage 1 is defined as the presence of b-cell autoimmunity as evidenced by the presence of two or more islet autoantibodies with normoglycemia and is presymptomatic, stage 2 as the presence of b-cell autoimmunity with dysglycemia and is presymptomatic, and stage 3 as onset of symptomatic disease. Adoption of this staging classification provides a standardized taxonomy for type 1 diabetes and will aid the development of therapies and the design of clinical trials to prevent symptomatic disease, promote precision medicine, and provide a framework for an optimized benefit/risk ratio that will impact regulatory approval, reimbursement, and adoption of interventions in the early stages of type 1 diabetes to prevent symptomatic disease.

UR - http://www.scopus.com/inward/record.url?scp=84962430639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962430639&partnerID=8YFLogxK

U2 - 10.2337/dc15-1419

DO - 10.2337/dc15-1419

M3 - Article

C2 - 26404926

AN - SCOPUS:84962430639

VL - 38

SP - 1964

EP - 1974

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -